| Management target | Revenue 11.0% FY29 |
|---|
| Revenue growth | 8.2% YoY consolidated growth. |
|---|---|
| Margins | EBITDA margin 8.8%; targeting double-digit margins via cost optimization. |
| Order book | Excess of INR 250 crores in hand for Europe. |
| Demand visibility | Strong secondary demand in emerging markets; domestic seasonality impacted Q1. |
| Management confidence | High on domestic growth and efficiency measures. |
Growth
Consolidated revenue grew 8.2% YoY; domestic formulations grew 5.8% to INR 2,040 million; API business surged 42.4% YoY.
Outlook
Targeting double-digit EBITDA margins; plans to repay INR 260 Cr debt within 18 months; maintenance capex limited to INR 50 Cr.
Risks
Gross margins impacted by 200 bps due to raw material price hikes and war-related supply chain disruptions.
Last quarter's promises, checked
Delivered
- Guided US sterile sales from 2nd sites → Delivered 62.2% US growth (= BEAT)
- Guided 140 Cr debt repayment/year → Delivered 930 Cr debt from 960 Cr (= BEAT)
- Guided double-digit EBITDA margin → Delivered 10.9% consolidated (= BEAT)
Partly delivered
- Guided MMP efficiency gains → Delivered 26% fewer batches but margins still pressured (= PARTIAL)
Missed
- Guided India growth in line with IPM → Delivered 5.8% vs muted seasonality (= MISS)
Investor Presentation filed with BSE, NSE: INDOCO. Summary written with AI assistance from the document.
Indoco Remedies Ltd: key numbers
- Share price
- ₹254.46
- Market cap
- ₹2,349 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 417.2×Sector 50.4×
- Promoter holding
- 58.86%+0.00% QoQ
- FII holding
- 1.27%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Other Announcement
Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.
Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr
Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.
- Value
- ₹0.01 Cr
Indoco Remedies Annual General Meeting
Indoco Remedies filed proceedings of its 79th AGM held on 17 September 2026. Shareholders voted on nine resolutions including dividend and borrowing limits.
Indoco Remedies Promoter Buying
Indoco Remedies promoter Aditi M. Panandikar and PAC bought 38,930 shares on the open market, raising aggregate holding to 7.30%. No transaction price is disclosed in the filing.
- Promoter stake change
- +0.04%
Indoco Remedies Promoter Buying: ₹0.92 Cr
Promoters Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare acquired Indoco Remedies Ltd shares via market purchases, totaling ₹0.92 Crore.
- Value
- ₹0.92 Cr
Indoco Remedies Business Update
Indoco Remedies received seven USFDA observations in Form 483 for its Plant II (Sterile) facility in Goa following an inspection from August 27 to September 4, 2026.